Drug
Surovatamig
Surovatamig is a pharmaceutical drug with 5 clinical trials. Currently 5 active trials ongoing.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
5(100%)
Phase Distribution
Ph phase_1
2
40%
Ph phase_3
1
20%
Ph phase_2
2
40%
Phase Distribution
2
Early Stage
2
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
2(40.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
5
trials recruiting
Total Trials
5
all time
Status Distribution
Active(5)
Detailed Status
Recruiting5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
5
Success Rate
N/A
Most Advanced
Phase 3
Trials by Phase
Phase 12 (40.0%)
Phase 22 (40.0%)
Phase 31 (20.0%)
Trials by Status
recruiting5100%
Recent Activity
5 active trials
Showing 5 of 5
recruitingphase_2
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
NCT07571746
recruitingphase_1
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038
recruitingphase_3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06549595
recruitingphase_2
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT06526793
recruitingphase_1
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
NCT07201558
Clinical Trials (5)
Showing 5 of 5 trials
NCT07571746Phase 2
A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease
NCT06564038Phase 1
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06549595Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
NCT06526793Phase 2
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
NCT07201558Phase 1
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5